

24 April 2023

**Cizzle Biotechnology Holdings Plc**  
("Cizzle Biotechnology" or the "Company")

**New Research Agreement with the University of York for Cancer Diagnosis and Therapy**

Cizzle Biotechnology, the UK based diagnostics developer, is pleased to announce that following successful results from its current research programme with the University of York, due to end this year, that it has today signed a new research agreement with the University for the further development and validation of its CIZ 1B biomarker technology for early stage cancer diagnosis and other potential applications in cancer therapy.

This includes the evaluation of the Company's proprietary biomarker for detecting a range of cancers in addition to the existing programme for early lung cancer detection.

**Highlights**

- New 12-month research and development agreement with the University of York
- Builds on successful outcomes of current research programme on meeting key milestones for monoclonal antibody characterization and assay platform optimization
- All intellectual property rights arising from the work to be owned by the Company
- Extends access to state of the art facilities and world leading scientists to support new solutions for early cancer diagnostics and therapeutic tools

This new agreement will extend the work being conducted at the university until 25th September 2024 and follows the successful programme initially announced on 17 September 2021 and further extended to June 2023. With a focus on the development and validation of molecular tools with potential application in cancer diagnosis or therapy, significant progress has been made in characterising and optimizing the company's antibodies for use and scale up into the configuration required for further clinical trials ahead of the launch of commercial early stage lung cancer assays. As in previous agreements, Cizzle Biotechnology will own all intellectual property rights arising from the work which strengthens the Company's position in creating new solutions for early cancer diagnostics and therapeutic tools.

Cizzle Biotechnology was a spin out from the University of York based on research and development by Professor Dawn Coverley at the University and the first company from the university to be listed on the London Stock Exchange. The company has a proven and long-term commitment to work with the University of York which provides access to its leading-edge research facilities and expertise.

**Commenting, Allan Syms, Executive Chairman of Cizzle Biotechnology, said:**"I am delighted to further extend our relationship with the University of York and in particular the leading-edge research being carried out in Professor Dawn Coverley's laboratories. The continuity and commitment of the researchers at the University has been a key building block in the development and commercialization of the CIZ1B biomarker for early cancer diagnosis. The current research programme has met some critical milestones, especially in optimising the platform and antibodies required to scale up and bring to market our diagnostic tests for early stage cancer detection. This new agreement will continue our access to state of the art research facilities and world leading scientists as we pursue our plans to bring early detection tests for lung cancer and potentially other forms of cancer."

**Enquiries:**

<b>Cizzle Biotechnology Holdings plc</b> Allan Syms (Executive Chairman)	Via IFC Advisory
<b>Allenby Capital Limited</b> John Depasquale Alex Brearley	+44(0) 20 33285656
<b>Novum Securities Limited</b> Colin Rowbury Jon Bellis	+44(0) 20 7399 9400
<b>IFC Advisory Limited</b> Tim Metcalfe Florence Chandler	+44(0) 20 3934 6630

**About the Company**

Cizzle Biotechnology is developing a blood test for the early detection of lung cancer. Cizzle Biotechnology is a spin-out from the University of York, founded in 2006 around the work of Professor Coverley and colleagues. Its proof-of-concept prototype test is based on the ability to detect a stable plasma biomarker, a variant of CIZ1 known as CIZ1B. CIZ1 is a naturally occurring cell nuclear protein involved in DNA replication, and the targeted CIZ1B variant is highly correlated with early stage lung cancer.

with early stage lung cancer.

For more information please see <https://cizzlebiotechnology.com>

You can also follow the Company through its twitter account @CizzlePlc and on LinkedIn.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [ms@seg.com](mailto:ms@seg.com) or visit [www.ms.com](http://www.ms.com).

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

MSCITMMTMTJTMTJ